Management

Pratik Shah, Ph.D. – President and Chief Executive Officer

Dr. Shah has served as our President and Chief Executive Officer since October 2013 and as a member of our board of directors since June 2007.

| read more »

John Schmid – Chief Financial Officer

John Schmid joined us as Chief Financial Officer in September 2013. Before joining us, Mr. Schmid co- founded Trius Therapeutics, Inc., a publicly-traded biopharmaceutical company, where he served as the Chief Financial Officer from June 2004 until its merger with Cubist Pharmaceuticals, Inc. in September 2013.

| read more »

David Stamler, M.D. – Chief Medical Officer

Dr. Stamler has served as our Chief Medical Officer since January 2011. Prior to joining us, Dr. Stamler served as Senior Vice President and Chief Medical Officer at XenoPort, Inc., a publicly-traded biopharmaceutical company, from 2008 to 2010 and Chief Scientific Officer and Head of Drug Development at Prestwick Pharmaceuticals, Inc., a private pharmaceutical company, from 2005 to 2008.

| read more »

Samuel Saks, M.D. – Chief Development Officer

Dr. Saks joined us as our Chief Development Officer in November 2013 and has served as a member of our board of directors since September 2009.

| read more »

Bharatt Chowrira, Ph.D., J.D. – Chief Operating Officer

Dr. Chowrira joined us as Chief Operating Officer in October 2013. Prior to joining us, Dr. Chowrira served as President and Chief Executive Officer of Addex Therapeutics, Inc., a biotechnology company publicly-traded on the SIX Swiss Exchange, from August 2011 to July 2013.

| read more »

Andreas Sommer, Ph.D. – Chief Scientific Officer

Dr. Sommer joined us as Chief Operating Officer in 2009 and became our Chief Scientific Officer in October 2013. Prior to joining us, Dr. Sommer served as Senior Vice President—Research and then President and Chief Executive Officer of Celtrix Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, from 1995 until it was acquired by Insmed, Inc., a biopharmaceutical company, in 2000.

| read more »

Arvind Sreedharan – Vice President of Marketing

Arvind Sreedharan joined us as Vice President of Marketing in January 2014. Prior to joining us, Mr. Sreedharan served as Director of Movement Disorder Marketing at Lundbeck LLC, an international pharmaceutical company.

| read more »

Matt Moran – Vice President of Regulatory Affairs

Matt Moran joined us as Vice President of Regulatory Affairs in January 2013. Prior to joining us, Matt served as Senior Director of Regulatory Affairs at Santarus, Inc., where he worked on the 505(b)(2) NDA submission and approval of Uceris®, which primarily led to the company’s acquisition by Salix Pharmaceuticals in 2013. Prior to Santarus, Inc., Matt held positions of increasing responsibility in regulatory affairs at Allergan, Nexbio, Therapeutics, Inc., Chugai Pharma, Agouron, Dura Pharmaceuticals and Wyeth, Inc.

| read more »

Michael Huang, M.D. – Vice President, Clinical Development

Michael Huang joined us in January 2014 as Vice President of Clinical Development. Prior to joining us, Dr. Huang served as Senior Medical Director at Santarus, Inc., that was recently acquired by Salix Pharmaceuticals. Before joining Santarus, Dr. Huang held positions of increasing responsibility in drug development at Valeant Pharmaceuticals, Phenomix Corporation and Spectrum Pharmaceuticals.

| read more »

Joanne Peake – Vice President of Clinical Operations

Joanne Peake joined us as Vice President of Clinical Operations in January 2014. Prior to joining us, Ms. Peake served as the Senior Director of Clinical Operations from 2009 until 2014 at Santarus, Inc., a publically traded pharmaceutical company, which was recently purchased by Salix Pharmaceuticals.

| read more »